- Home
- VKTX vs PRCT Comparison
VKTX vs PRCT Comparison
Compare VKTX & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VKTX
- PRCT
- Stock Information
- Founded
- VKTX 2012
- PRCT 2009
- Country
- VKTX United States
- PRCT United States
- Employees
- VKTX N/A
- PRCT N/A
- Industry
- VKTX Biotechnology: Pharmaceutical Preparations
- PRCT Medical Specialities
- Sector
- VKTX Health Care
- PRCT Health Care
- Exchange
- VKTX Nasdaq
- PRCT Nasdaq
- Market Cap
- VKTX 2.8B
- PRCT 3.2B
- IPO Year
- VKTX 2015
- PRCT 2021
- Fundamental
- Price
- VKTX $28.14
- PRCT $59.80
- Analyst Decision
- VKTX Buy
- PRCT Strong Buy
- Analyst Count
- VKTX 12
- PRCT 7
- Target Price
- VKTX $84.00
- PRCT $90.00
- AVG Volume (30 Days)
- VKTX 3.9M
- PRCT 770.9K
- Earning Date
- VKTX 07-23-2025
- PRCT 07-31-2025
- Dividend Yield
- VKTX N/A
- PRCT N/A
- EPS Growth
- VKTX N/A
- PRCT N/A
- EPS
- VKTX N/A
- PRCT N/A
- Revenue
- VKTX N/A
- PRCT $249,121,000.00
- Revenue This Year
- VKTX N/A
- PRCT $47.40
- Revenue Next Year
- VKTX N/A
- PRCT $31.55
- P/E Ratio
- VKTX N/A
- PRCT N/A
- Revenue Growth
- VKTX N/A
- PRCT 59.36
- 52 Week Low
- VKTX $18.92
- PRCT $47.04
- 52 Week High
- VKTX $81.73
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- VKTX 55.39
- PRCT 47.27
- Support Level
- VKTX $25.80
- PRCT $56.00
- Resistance Level
- VKTX $28.80
- PRCT $60.02
- Average True Range (ATR)
- VKTX 1.65
- PRCT 2.02
- MACD
- VKTX 0.11
- PRCT -0.42
- Stochastic Oscillator
- VKTX 86.93
- PRCT 34.04
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.